Efficacy and safety of Montelukast sodium combined with salmeterol ticasone in the treatment of bronchial asthma
Objective:To investigate the effects of Montelukast sodium combined with salmeteroticasone on lung function and serum Chemotine-like factor-1(CKLF-1)and Nicotinamide phosphoribosyl transferase(NAMPT)levels in patients with Bronchial asthma(BA).levels.Methods:A total of 132 patients with BA who were hospitalized in our hospital from December 2020 to December 2022 were selected as the research subjects and randomly divided into a reference group and a study group,with 66 cases in each group.The reference group was treated with salmeterol and fluticasone powder,while the study group was treated with salmeterol and fluticasone powder in combination with montelukast sodium on the basis of the reference group.The clinical efficacy,blood gas analysis indicators,lung function indicators,serum cytokine levels,and adverse reaction rates were compared between the two groups.Results:The total clinical effective rate in the study group was significantly higher than that in the reference group(P<0.05).After treatment,the arterial partial pressure of oxygen(PaO2),forced expiratory volume in 1 second(FEV1),FEV1/forced vital capacity(FEV1C/FVC),peak expiratory flow rate(PEF),maximum middle expiratory flow rate(MMEF)in the study group were significantly higher than those in the reference group,while the carbon dioxide partial pressure(PaCO2),interleukin-17(IL-17),CKLF-1,NAMPT,tumor necrosis factor-α(TNF-α)levels were significantly lower than those in the reference group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Salmeterol ticasone and Montelukast sodium in the treatment of DA is effective,can reduce inflammation,improve blood gas analysis index,promote the improvement of lung function,and is safe and reliable.
Salmeterol ticasone powderMontelukast sodiumBronchial asthmaBlood gas analysis
NETL
NSTL
万方数据
